461 related articles for article (PubMed ID: 18444791)
1. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
[TBL] [Abstract][Full Text] [Related]
2. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
[TBL] [Abstract][Full Text] [Related]
3. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
Stryjewski ME; Chu VH; O'Riordan WD; Warren BL; Dunbar LM; Young DM; Vallée M; Fowler VG; Morganroth J; Barriere SL; Kitt MM; Corey GR;
Antimicrob Agents Chemother; 2006 Mar; 50(3):862-7. PubMed ID: 16495243
[TBL] [Abstract][Full Text] [Related]
4. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures.
Wilson SE; O'Riordan W; Hopkins A; Friedland HD; Barriere SL; Kitt MM;
Am J Surg; 2009 Jun; 197(6):791-6. PubMed ID: 19095213
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections.
Laohavaleeson S; Barriere SL; Nicolau DP; Kuti JL
Pharmacotherapy; 2008 Dec; 28(12):1471-82. PubMed ID: 19025428
[TBL] [Abstract][Full Text] [Related]
6. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
7. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.
Chang MH; Kish TD; Fung HB
Clin Ther; 2010 Dec; 32(13):2160-85. PubMed ID: 21316534
[TBL] [Abstract][Full Text] [Related]
8. Telavancin: a novel lipoglycopeptide.
Saravolatz LD; Stein GE; Johnson LB
Clin Infect Dis; 2009 Dec; 49(12):1908-14. PubMed ID: 19911938
[TBL] [Abstract][Full Text] [Related]
9. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
Leonard SN; Rybak MJ
Pharmacotherapy; 2008 Apr; 28(4):458-68. PubMed ID: 18363530
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
Yin LY; Calhoun JH; Thomas TS; Wirtz ED
J Antimicrob Chemother; 2009 Feb; 63(2):357-60. PubMed ID: 19060292
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
12. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections.
Barriere SL
Future Microbiol; 2010 Dec; 5(12):1765-73. PubMed ID: 21080861
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
[TBL] [Abstract][Full Text] [Related]
14. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children.
Wible K; Tregnaghi M; Bruss J; Fleishaker D; Naberhuis-Stehouwer S; Hilty M
Pediatr Infect Dis J; 2003 Apr; 22(4):315-23. PubMed ID: 12690270
[TBL] [Abstract][Full Text] [Related]
15. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
Davis SL; McKinnon PS; Hall LM; Delgado G; Rose W; Wilson RF; Rybak MJ
Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
Krause KM; Barriere SL; Kitt MM; Benton BM
Diagn Microbiol Infect Dis; 2010 Oct; 68(2):181-5. PubMed ID: 20846593
[TBL] [Abstract][Full Text] [Related]
17. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
[TBL] [Abstract][Full Text] [Related]
19. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
Wilcox MH; Tack KJ; Bouza E; Herr DL; Ruf BR; Ijzerman MM; Croos-Dabrera RV; Kunkel MJ; Knirsch C
Clin Infect Dis; 2009 Jan; 48(2):203-12. PubMed ID: 19072714
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
Noel GJ; Bush K; Bagchi P; Ianus J; Strauss RS
Clin Infect Dis; 2008 Mar; 46(5):647-55. PubMed ID: 18225981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]